Stay updated on Pembrolizumab for Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab for Hepatocellular Carcinoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRevision: v3.3.4 replaces the previous v3.3.3 revision on the page. This appears to be a minor version update with no substantive changes to study content.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedFooter updates remove 'HHS Vulnerability Disclosure' and add a revision label 'Revision: v3.3.3'. The study content and status remain unchanged.SummaryDifference0.1%

- Check59 days agoChange DetectedAdded a note that publications are automatically filled from PubMed and may not all relate to the study, and updated the page revision to v3.3.2. The corresponding deletions reference PubMed-derived publications and list revision v3.2.0.SummaryDifference0.1%

- Check66 days agoChange DetectedRemoved the government funding status banner that warned about potential data delays and directed users to opm.gov for updates.SummaryDifference0.4%

- Check81 days agoChange DetectedUI/layout updates were applied to the Study Details page with no substantial changes to core study information such as eligibility, enrollment, endpoints, or timelines. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check109 days agoChange DetectedIntroducing version v3.2.0 and a government-operating-status notice; removing the older v3.1.0 reference.SummaryDifference3%

Stay in the know with updates to Pembrolizumab for Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Hepatocellular Carcinoma Clinical Trial page.